Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 54, n° 6
pages 1099-1101 (juin 2006)
Doi : 10.1016/j.jaad.2005.08.032
CASE REPORT

Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept
 

James M. Krell, MD
From the Total Skin and Beauty Dermatology Center, Birmingham 

Correspondence to: James M. Krell, MD, Total Skin and Beauty Dermatology Center, 2100 16th Ave South, Ste 202, Ash Place, Birmingham, AL 35205.

Birmingham, Alabama

Abstract

This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.

The full text of this article is available in PDF format.

 Funding sources: Research support from Abbott Laboratories, Biogen Idec, Genentech, and Synta Pharmaceuticals.
Conflicts of interest: Dr Krell is a consultant and speakers’ bureau participant for Amgen, Biogen Idec, and Genentech.
Reprints not available from the author.



© 2006  American Academy of Dermatology, Inc.@@#104156@@